E-174 Recognition of SAH patients at high risk for symptomatic vasospasm: responses to acetazolamide challenge

Introduction Cerebral vasospasm can be a devastating sequela of aneurysmal SAH. There is neither a satisfactory predictor nor a standardized protocol for its early detection. We evaluated cone beam CT perfusion (CBCTP) with acetazolamide challenge as a potential tool to detect deficiencies in autoregulation prior to development of symptomatic vasospasm. Methods Ten patients presenting with aneurysmal SAH within 24 hours of symptom onset were enrolled in this pilot study. Just prior to the initial DSA study, a baseline CBCTP acquisition was performed (60 cc contrast, 60 cc saline). Acetazolamide (1 g IV) was administered and, after a 20-minute delay, a second CBCTP acquisition was done. Data was then reconstructed into perfusion maps (CBF, CBV, and MTT). Delay insensitive deconvolution was used and AIFs were manually selected. Motion correction was applied if possible. Data was analyzed for percent change in perfusion maps in response to acetazolamide, variation between cerebral hemispheres, and study related complications. Percent change in CBF with a p value Results Perfusion maps were successfully acquired for all 10 patients. Our analysis was performed on 20 cerebral hemispheres (right and left). Nineteen hemispheres demonstrated a significant change in CBF in response to acetazolamide (p Conclusion Accurate early identification of patients at high risk for symptomatic vasospasm would be a valuable clinical tool in the management of aneurysmal SAH. This small pilot study shows the feasibility of CBCTP with acetazolamide challenge to generate reproducible, diagnostic quality perfusion maps with a response to acetazolamide. These provide the opportunity to evaluate the vasodilatory capacity or state of autoregulation at a time before vasospasm is angiographically or symptomatically evident. A larger study is ongoing to provide data which will help to better understand the significance of changes observed in our study. Disclosures D. Dawkins: None. E. Harvey: None. K. Li: None. B. Aagaard-Kienitz: None. D. Niemann: None. M. Baskaya: None. S. Schafer: 1; C; Siemens Research Support - Multi-phasic acquisition and reconstruction under development. Not available for sale in the U.S.A.. C. Strother: None. A. Ahmed: 2; C; Siemens.